Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MIRM 
Mirum Pharmaceuticals Inc (MIRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: MIRM (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 10.98% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.46B USD | Price to earnings Ratio - | 1Y Target Price 68.6 |
Price to earnings Ratio - | 1Y Target Price 68.6 | ||
Volume (30-day avg) 414030 | Beta 0.95 | 52 Weeks Range 27.10 - 54.23 | Updated Date 06/14/2025 |
52 Weeks Range 27.10 - 54.23 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.39% | Operating Margin (TTM) -13.61% |
Management Effectiveness
Return on Assets (TTM) -7.11% | Return on Equity (TTM) -33.06% |
Valuation
Trailing PE - | Forward PE 39.68 | Enterprise Value 2497889607 | Price to Sales(TTM) 6.48 |
Enterprise Value 2497889607 | Price to Sales(TTM) 6.48 | ||
Enterprise Value to Revenue 6.51 | Enterprise Value to EBITDA -8.85 | Shares Outstanding 49534700 | Shares Floating 39542072 |
Shares Outstanding 49534700 | Shares Floating 39542072 | ||
Percent Insiders 2.04 | Percent Institutions 114.23 |
Analyst Ratings
Rating 4.6 | Target Price 68.6 | Buy 4 | Strong Buy 6 |
Buy 4 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Mirum Pharmaceuticals Inc
Company Overview
History and Background
Mirum Pharmaceuticals Inc. was founded in 2018, focusing on developing and commercializing novel therapies for debilitating liver diseases. It acquired assets from other companies to build its pipeline and has grown through strategic acquisitions and clinical development.
Core Business Areas
- Hepatology: Focuses on the development and commercialization of therapies for liver diseases, particularly rare and pediatric cholestatic liver diseases.
Leadership and Structure
The company is led by its CEO, Chris Peetz, and has a management team with experience in the pharmaceutical industry. It follows a typical corporate structure with departments focused on R&D, commercialization, and administration.
Top Products and Market Share
Key Offerings
- LIVMARLI (maralixibat): LIVMARLI is approved for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Revenue from LIVMARLI in 2023 was approximately $128 million. Competitors include other symptomatic treatments and potential gene therapies for ALGS and PFIC.
- Volixibat: Volixibat is an investigational drug for treating adult cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). It is currently in Phase 3 development. No current revenue. Competition will arise from existing treatment options (e.g., ursodeoxycholic acid for PBC) and other emerging therapies targeting similar pathways.
Market Dynamics
Industry Overview
The rare liver disease market is characterized by high unmet needs and limited treatment options. It's a niche market with potential for high prices due to the lack of competition and the severity of the conditions.
Positioning
Mirum is positioned as a leader in developing therapies for rare cholestatic liver diseases, particularly in pediatric populations. Its competitive advantage lies in its focus on this specific niche and its expertise in developing drugs for these conditions.
Total Addressable Market (TAM)
The TAM for Mirum's existing and pipeline products is estimated to be in the billions of dollars, considering the prevalence of ALGS, PFIC, PBC, and PSC. Mirum is well-positioned to capture a significant share of this market with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Approved product (LIVMARLI) generating revenue
- Strong focus on rare liver diseases
- Experienced management team
- Advanced clinical pipeline
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Small market size for rare diseases
- Potential for competition from larger pharmaceutical companies
Opportunities
- Expansion of LIVMARLI into new indications
- Successful development and commercialization of volixibat
- Acquisition of additional assets or companies
- Geographic expansion into new markets
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing similar therapies
- Pricing pressure from payers
Competitors and Market Share
Key Competitors
- CYTK
- ICPT
- GNFT
Competitive Landscape
Mirum faces competition from companies developing therapies for liver diseases, including those targeting similar pathways. Its competitive advantage lies in its focus on rare pediatric cholestatic liver diseases and its first-mover advantage with LIVMARLI.
Major Acquisitions
Disorder S.A.
- Year: 2021
- Acquisition Price (USD millions): 210
- Strategic Rationale: Acquisition of Disorder S.A. for volixibat, expanding Mirum's pipeline.
Growth Trajectory and Initiatives
Historical Growth: Mirum's growth has been driven by the commercialization of LIVMARLI and the progress of its clinical pipeline.
Future Projections: Analysts project continued revenue growth for LIVMARLI and potential upside from the successful development and commercialization of volixibat.
Recent Initiatives: Recent initiatives include the ongoing clinical trials for volixibat in PBC and PSC, as well as efforts to expand the market reach of LIVMARLI.
Summary
Mirum Pharmaceuticals is a growing biopharmaceutical company focused on rare liver diseases. LIVMARLI is driving revenue, and volixibat has significant potential. High R&D spending and regulatory hurdles are risks. Mirum needs to expand their treatment options and should be cautious of larger companies in the same space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Mirum Pharmaceuticals Inc. Investor Relations, SEC filings, Analyst reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary. Always consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mirum Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2019-07-18 | CEO & Director Mr. Christopher Peetz | ||
Sector Healthcare | Industry Biotechnology | Full time employees 334 | Website https://www.mirumpharma.com |
Full time employees 334 | Website https://www.mirumpharma.com | ||
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.